Bard, J&J face another vaginal mesh lawsuit; Komen foundation accused of exaggerating mammogram benefits;

 @FierceMedDev: Globus scales back its IPO pricing, now trading under GMED. More | Follow @FierceMedDev

 @MarkHFierce: Thoratec reported a Q2 loss but is banking on continued sales growth to carry the year. More | Follow @MarkHFierce

 @DamianFierce: Study: U.S. access to new devices no slower than EU's. More | Follow @DamianFierce

> C. R. Bard ($BCR) and Johnson & Johnson ($JNJ) are facing more lawsuits over the Gynecare transvaginal mesh, with a Florida plaintiff claiming significant injuries as result of the embattled implant. News

> In the British Medical Journal, researchers are accusing the Susan G. Komen for the Cure of vastly overstating the benefits of mammography, while almost entirely ignoring the procedure's risks. More

> The Medical College of Wisconsin is conducting a clinical study of InTone, an FDA-cleared device to treat female urinary incontinence. Release

> Intelligent Ultrasound, a diagnostics firm spun-out from Oxford University, signed on to develop Dx software for the U.K.'s National Health Service, expecting to save the agency $62 million per year. Article

> Dental products maker Sirona ($SIRO) topped analysts estimates in its third quarter, reporting net income of $30.3 million, down from last year's $36.3 million. Item

Biotech News

 @FierceBiotech: Yesterday's most popular story: Analyst reads last rites after heart failure scuttles Bristol hepatitis C study. Story | Follow @FierceBiotech

 @JohnCFierce: Bankers tally torrid pace for biotech M&A as hungry suitors pounce. More | Follow @JohnCFierce

 @RyanMFierce: A record for GSK? Asks for FDA approval for targeted melanoma treatment roughly 3 years after hitting the clinic. More | Follow @RyanMFierce

> J&J's boost in Doxil supply benefits study of Endocyte/Merck drug. Article

> Biotech startup Atterocor grabs $16M A round for cancer compound. More

> H1 venture deals: Celladon moves up in the rankings. Update

> Burrill & Co. boosts latest life sciences fund to $505M. News

> GSK races to regulators for approvals of new skin cancer drugs. Article

Pharma News

 @FiercePharma: More on "how not to insider trade," with Bristol-Myers exec as exhibit A, from The Wall Street JournalMore | Follow @FiercePharma

> J&J acknowledges what everyone knows, it settled with DoJ. Story

> Johnson & Johnson releases some Doxil for trials. More

> Investors bite on Pfizer's Sandwich site. News

> GSK tries volume, goodwill, over margins in Africa. Article

> Bloomberg: India's Sun sizes up deal with Germany's Stada. Story